PRTA
Prothena Corporation plc
NASDAQ · Healthcare · Biotechnology · IE
$9.82
+2.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 54.5M | 9.7M | 135.2M | 91.4M | 53.9M |
| Cost of Revenue | 30.8M | 3.7M | — | — | — |
| Gross Profit | 23.7M | 6.0M | 135.2M | 91.4M | 53.9M |
| Operating Expenses | |||||
| R&D Expense | 64.9M | 134.9M | 222.5M | 220.6M | 135.6M |
| SG&A Expense | 49.4M | 59.4M | 67.2M | 61.8M | 49.9M |
| General & Admin Expense | 49.4M | 59.4M | 67.2M | 61.8M | 49.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (27.9M) | (3.7M) | — | — | — |
| Total Operating Expenses | 86.5M | 190.5M | 289.7M | 282.4M | 185.5M |
| Cost and Expenses | 117.3M | 194.2M | 289.7M | 282.4M | 185.5M |
| Operating Income (EBIT) | (62.8M) | (184.6M) | (154.6M) | (191.0M) | (131.6M) |
| Non-Operating | |||||
| Interest Income | 11.0M | 14.1M | 25.8M | 31.0M | 6.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 11.0M | 14.1M | 25.8M | 31.0M | 6.3M |
| Other Non-Op Income/Expense | 19.2M | (16.3M) | 25.6M | 30.6M | 6.0M |
| Non-Operating Income (excl Interest) | (19.2M) | 16.3M | (25.6M) | (30.6M) | (6.0M) |
| EBT (Pre-Tax Income) | (43.6M) | (200.8M) | (128.9M) | (160.5M) | (125.6M) |
| Income Tax Expense | 384.0K | 43.3M | (6.6M) | (13.5M) | (8.7M) |
| Bottom Line | |||||
| Net Income | (44.0M) | (244.1M) | (122.3M) | (147.0M) | (116.9M) |
| Earnings from Cont. Ops | (44.0M) | (244.1M) | (122.3M) | (147.0M) | (116.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (44.0M) | (244.1M) | (122.3M) | (147.0M) | (116.9M) |
| Per Share | |||||
| Basic EPS | ($0.83) | ($4.53) | ($2.27) | ($2.76) | ($2.47) |
| Diluted EPS | ($0.84) | ($4.53) | ($2.27) | ($2.76) | ($2.47) |
| Revenue Per Share | $1.05 | $0.18 | $2.51 | $1.72 | $1.14 |
| Shares | |||||
| Basic Shares Outstanding | 52.1M | 53.8M | 53.8M | 53.2M | 47.4M |
| Diluted Shares Outstanding | 52.1M | 53.8M | 53.8M | 53.2M | 47.4M |
| Profitability Metrics | |||||
| EBITDA | (41.1M) | (197.1M) | (128.0M) | (159.6M) | (124.9M) |
| D&A | 2.5M | 3.7M | 893.0K | 928.0K | 744.0K |
| EBIT | (43.6M) | (200.8M) | (128.9M) | (160.5M) | (125.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026